Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
While CAR T-cell therapy has shown promising results for hematological malignancies, Claudia Rössig, MD University of Münster, Münster, Germany, discusses the issues with using this therapy for solid cancers. Dr Rössig was speaking from the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).